An Uncontrolled Phase II, Multi Center Trial Evaluating Antitumor Efficacy and Safety of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Inclusion Criteria:

- measurable disease as defined by the presence of at least one
measurable lesion - prior immunotherapy (up to 2 regimens) or prior radiotherapy is
permitted but at least 4 weeks must have elapsed prior to enter study - life expectancy
of at least 12 weeks - adequate bone marrow, liver and kidney function Exclusion
Criteria: - excluded medical conditions like: pre-existing neuropathy, active heart
diseases or ischemia, serious infections, HIV infection, chronic hepatitis B or C, brain
metastasis, seizures, hypersensitivity to taxanes, organ transplants, some previous
cancers - excluded therapies and medications, previous and concomitant such as:
anticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to study
entry; more than two prior anticancer chemotherapy regimens; radiotherapy during study or
within 4 weeks prior to study entry; bone marrow transplant - others: pregnant or
breast-feeding patients; both men and women enrolled in this trial must use adequate
barrier birth control measures during the course of the trial; substance abuse, medical,
psychological or social conditions that may interfere with the patient's participation.